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Abstract
Background: Vitamin A deficiency (VAD) is an important nutritional problem in India, resulting in an increased risk of severe
morbidity and mortality. Periodic, high-dose vitamin A supplementation is the WHO-recommended method to prevent
VAD, since a single dose can compensate for reduced dietary intake or increased need over a period of several months.
However, in India only 34 percent of targeted children currently receive the two doses per year, and new strategies are
urgently needed.
Methodology: Recent advancements in biotechnology permit alternative strategies for increasing the vitamin A content of
common foods. Mustard (Brassica juncea), which is consumed widely in the form of oil by VAD populations, can be
genetically modified to express high levels of beta-carotene, a precursor to vitamin A. Using estimates for consumption, we
compare predicted costs and benefits of genetically modified (GM) fortification of mustard seed with high-dose vitamin A
supplementation and industrial fortification of mustard oil during processing to alleviate VAD by calculating the avertable
health burden in terms of disability-adjusted life years (DALY).
Principal Findings: We found that all three interventions potentially avert significant numbers of DALYs and deaths.
Expanding vitamin A supplementation to all areas was the least costly intervention, at $23–$50 per DALY averted and
$1,000–$6,100 per death averted, though cost-effectiveness varied with prevailing health subcenter coverage. GM
fortification could avert 5 million–6 million more DALYs and 8,000–46,000 more deaths, mainly because it would benefit the
entire population and not just children. However, the costs associated with GM fortification were nearly five times those of
supplementation. Industrial fortification was dominated by both GM fortification and supplementation. The cost-
effectiveness ratio of each intervention decreased with the prevalence of VAD and was sensitive to the efficacy rate of
averted mortality.
Conclusions: Although supplementation is the least costly intervention, our findings also indicate that GM fortification
could reduce the VAD disease burden to a substantially greater degree because of its wider reach. Given the difficulties in
expanding supplementation to areas without health subcenters, GM fortification of mustard seed is an attractive alternative,
and further exploration of this technology is warranted.
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Introduction
Vitamin A deficiency (VAD) is an important nutritional
problem in large parts of the developing world, affecting as many
as 130 million children [1]. VAD results in an increased risk
of severe morbidity and mortality due to anemia and depressed
resistance to infectious disease and is responsible for more than a
million child deaths annually. The most apparent result of VAD is
clinical eye symptoms due to xerophthalmia (a destructive dryness
of the conjunctival epithelium, manifested in early stages by
deposits in the conjunctiva known as Bitot’s spots), making it the
leading cause of preventable childhood blindness in developing
countries [1]. VAD also affects many women in poor countries,
specifically causing night blindness, anemia, and increased mater-
nal morbidity and mortality during pregnancy and lactation.
Though the incidence of clinical VAD in India has declined
significantly over the past few decades, the country has the greatest
number (more than 35 million) and the greatest percentage of
VAD children in the world [1], and VAD persists as a public
health problem, especially in rural areas [2,3]. The overall
prevalence of xerophthalmia among children is 1.7 percent [4],
and approximately 0.8 percent of all children suffer from Bitot’s
spots [5], but state and local rates can vary significantly (Figure 1).
Subclinical VAD is even more prevalent, with recent estimates
(31–57 percent of children under six) placing India among the
highest in the world [1,4]. VAD also afflicts more than 12 percent
PLoS ONE | www.plosone.org 1 August 2010 | Volume 5 | Issue 8 | e12046of all mothers nationwide [6], and 19 states have night blindness
rates for pregnant women exceeding 5 percent [7].
VAD occurs primarily in the lower socioeconomic strata of poor
countries, among people with limited food choices and diets
predominated by less nutritious staple foods [8]. Strategies for
addressing VAD have traditionally fallen into three main cate-
gories: supplementation, food fortification, and diet and behavior
modification. Recent advancements in biotechnology have created
an additional avenue for addressing VAD: biofortification—using
genetic recombinant technology to develop genetically modified
(GM) fortified products with enhanced expression of provitamin A
carotenoids, such as vitamin A–enhanced rice, or ‘‘golden rice’’
[9]. It has been suggested that introducing golden rice in
India could decrease VAD prevalence by as much as 59 percent
[10], but people in some regions in India with a high prevalence
of VAD traditionally do not consume significant amounts of
rice. Moreover, the unconventional color of golden rice may
discourage its consumption, and poor people may not consume
enough fat to facilitate biological absorption of the carotenoids
[11–13].
However, rice is not the only crop that has been modified to
express high levels of beta-carotene; mustard (Brassica juncea) can be
modified to express significantly higher levels of beta-carotene, as
much as 600 mg/g [14,15]. In addition, beta-carotene levels are
conserved when the mustard seeds are pressed into oil, which is
widely consumed in many parts of India with a high prevalence of
VAD, even by lower socioeconomic groups (see Supplementary
Notes S1 and Supplementary Figures S1 and S2 for more
information on mustard oil consumption in India). Only a few
drops of the transgenic oil would satisfy the recommended daily
allowance for vitamin A intake.
Periodic, high-dose vitamin A supplementation is the most
widely used public health approach to preventing deficiency [16].
A single dose can provide a reserve of vitamin A to compensate for
reduced dietary intake or increased need over a period of several
months. However, in India the percentage of targeted children
currently receiving two doses per year, distributed by the
Reproductive and Child Health program, is reported to be
approximately 30 percent [6,17], and new strategies are urgently
needed. We examined the costs and health benefits of GM
fortification of mustard oil in India. Although several recent studies
have examined the possible effect of different genetically modified
foods [10,13,18,19], none have compared the costs and outcomes
of different approaches. Thus, in our cost-benefit analysis we
include three population-based strategies to improve the vitamin A
status of at-risk groups: high-dose vitamin A supplementation for
preschoolers (ages 1 to 4); industrial fortification of mustard oil
during processing; and GM fortification of mustard oil.
Our analysis focused on states in India that consume mustard
oil in significant quantities and that have been shown to have a
high prevalence of VAD. These include states where mustard is
grown and consumed (Uttar Pradesh, Bihar, Assam, West Bengal,
Madhya Pradesh, Rajasthan, Jharkhand, Orissa, Haryana,
Gujarat, Punjab, Jammu and Kashmir, and Himachal Pradesh)
and states where mustard is not grown but consumed (Manipur,
Nagaland, and Tripura). We also emphasized those states where
Bitot’s spots prevalence rates indicate that VAD is a public health
problem: Uttar Pradesh, Bihar, Assam, West Bengal, Madhya
Pradesh, Rajasthan, Jharkhand, and Tripura. These analyses
focused on the rural areas of these states, where the vast majority
of the population lives. Information on prevalence rates for urban
areas is not as comprehensively available as those for rural areas,
Figure 1. Prevalence of Bitot’s spots among children in 17 Indian states. Sources: * [42]; ** [5]; 6 [59]; { [60]; 1 [61].
doi:10.1371/journal.pone.0012046.g001
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Bureau (NNMB) focus their efforts. Hence, we included a subset
of states with urban prevalence estimates (Uttar Pradesh, Bihar,
West Bengal, Madhya Pradesh, Jharkhand, Jammu and Kashmir)
as well as the urban populations in two well-studied metropolitan
areas, Chandigarh and Delhi, for urban-specific analyses. The
implementation of health initiatives in India is typically the
responsibility of individual states, and it would make little sense for
states with low prevalence of VAD or negligible consumption of
mustard oil to participate in vitamin A GM fortification efforts.
Methods
We examined alternative population-based strategies to alleviate
VAD by calculating the avertable health burden in terms of
disability-adjusted life years (DALY) as well as avertable deaths
and by comparing incremental cost-effectiveness ratios (ICER) in
terms of unit cost per both DALY and death averted. DALYs are a
measure of healthy life years—the sum of the present value of
years of future lifetime lost through premature mortality plus the
present value of years of future lifetime, adjusted for the average
severity of the mental or physical disability caused by a disease or
injury [20]. The DALY metric allows comparisons of alternative
health strategies using a single index that combines information
about mortality and morbidity and has been widely used in similar
analyses [10,13,18,19].
We also calculated the effect of a specific intervention as the
number of DALYs averted, defined as
DALYsaverted~YLLavertedzYLDtemp,avertedzYLDperm,averted ð1Þ
where YLLaverted is the number of discounted life-years averted, and
YLDtemp,averted and YLDperm,averted are years of life with temporary
and permanent disability averted, respectively, due to morbidity.
To account for varying disease levels among the different target
groups affected by the three strategies, YLLaverted, YLDtemp,averted,
and YLDperm,averted are defined as follows:
YLLaverted~
X
j TjMaverted
j (1{e
{rLj)(1=r) ð2Þ
YLDtemp,averted~
X
k
X
j TjIaverted
kj Dkj(1{e{rt)(1=r) ð3Þ
YLDperm,averted~
X
l
X
j TjIaverted
lj Dlj(1{e
{rLj)(1=r) ð4Þ
where Tj is the total number of people in the target group j,
Maverted
j is the reduction in the mortality rate of the target group
due to the intervention and Lj is the average remaining life
expectancy. Iaverted
kj and Iaverted
lj are reductions in the morbidity
rates of temporary and permanent sequelae k and l, respectively.
Dkj and Dlj are the corresponding disability weights. The
parameter t is the duration of the intervention, and r is the
discount rate of future life years, which is the standard 3 percent
used in DALY calculations as recommended by the World Bank
[21].
We considered the effect of an intervention over a 20-year time
frame. We assumed that the reduction of temporary sequelae, such
as Bitot’s spots and night blindness, is impermanent, lasting only as
long as the duration of the intervention. For example, an
individual receiving vitamin A supplementation up to an age of
4 years could still develop Bitot’s spots at age 5, at which point the
intervention would have ceased for that individual. However,
permanent sequelae, such as blindness, are averted for the lifetime
of the treated individual, since the intervention allows an
individual to pass through the most high-risk period for the onset
of blindness unscathed. Second, we assumed that individuals
whose lives have been saved by the intervention go on to live for
their remaining life expectancy. Finally, we assumed that an
intervention lasting less than two years for a cohort of preschool
children would reduce neither the mortality rate nor permanent
sequelae among that cohort, since a single dose compensates for
reduced intake for only several months. Thus, we conservatively
assume that premature cessation of supplementation would put a
child at full risk of VAD morbidity and mortality.
We evaluated the cost-effectiveness of a particular intervention
relative to other possible interventions according to the ratio of its
total cost to its total effectiveness over the entire 20-year time
frame, assuming that the program is already running at full
capacity. Costs were discounted at a 3 percent annual rate.
Effectiveness is in terms of averted deaths or averted DALYs.
Because we lacked baseline data by state on current supplemen-
tation coverage, and anecdotal accounts suggest it is lower than
reported [22], we assumed that VAD data were collected in the
absence of an intervention. Hence, our baseline assumes that little
or no intervention currently exists, but we account for possible
underlying supplementation coverage by applying a range of
effectiveness rates. All ICERs express the incremental impact of
each non-dominated intervention. A larger cost-effectiveness ratio
indicates a higher cost per unit of health gained. Prior to the
calculation of ICERs, we excluded interventions that are strictly
dominated—that is, interventions that are both less effective and
more costly than at least one other strategy. In addition to
calculating the number of DALYs averted for each intervention,
we also calculated ICERs for deaths averted. Lastly, we attributed
a monetary value to a DALY to calculate internal rates of return
(IRR). The monetary value chosen was annual per capita income
for the year 2003–2004 [23]. As with similar analyses [13], the
IRR estimates generated should be interpreted carefully. The goal
of this approach was to estimate a useful metric for economic
analysis rather than to predict rates of return on investment. These
metrics offer an index, scaled to the average local living standard,
by which the comparative value of an intervention can be judged.
Finally, GM-fortified mustard is still in the research and
development stage. Hence, in this ex ante framework, parameters
such as program costs and the reductions in mortality and
morbidity rates are not yet known and must be estimated based on
assumptions about health services, agriculture, and food produc-
tion and delivery systems in India. All assumptions are based on
the best biomedical research available, drawn from published
studies as well as interviews with experts in VAD and mustard
production and consumption in India.
Data
Our analysis used state-specific data where possible to estimate
state-specific mustard oil consumption among young children and
women of reproductive age, as well as rates of effectiveness in
reducing morbidity and mortality associated with vitamin A
deficiency. We calculated all results in 2005 U.S. dollars, using the
exchange rate of Rs. 40=US$1.
Strategies
We analyzed three interventions: (1) high-dose vitamin A
supplementation; (2) industrial fortification of mustard oil; and (3)
GM fortification of mustard oil with genetically modified mustard
seed. Averted DALYs were calculated based on (1) avoided
VAD and Golden Mustard
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avoided mortality due to subclinical and clinical VAD. As in other
analyses [13], averted morbidity includes cases of Bitot’s spots and
night blindness during the intervention, as well as lifetime
disability due to blindness. Bitot’s spots and night blindness are
treated as temporary diseases, the durations of which are taken at
one year to avoid inflation of DALYs. For blindness, we con-
servatively assumed that the prevalence of corneal xerophthalmia
cases is one-tenth the prevalence of Bitot’s spots [24–29], and
without treatment, one-half of all corneal cases lead to blindness
[16]. Averted morbidity DALYs were calculated as the sum of
disability due to Bitot’s spots, night blindness, and blindness
multiplied by their respective treatment effectiveness rates.
Because data on prevalence rates are scant, other sequelae of
xerophthalmia due to VAD, such as corneal xerosis and keratoma-
lacia, are not considered. Consequently, estimates for averted
cotemporaneous disability are conservative.
High-dose vitamin A supplementation. We considered a
massive dose supplementation program providing semiannual
doses of 200,000IU to preschoolers, who are more responsive to
high-potency vitamin A supplementation and more susceptible to
corneal xerophthalmia [16]. It has been shown that vitamin A
supplementation does not benefit early infant survival [30–33].
The current vitamin A supplementation program in India
concentrates on children 9 to 36 months [34].
Because we lacked baseline data on the effectiveness of vitamin
A supplementation to reduce morbidity specific to our study areas,
we used a range of values reported in the literature (Table 1). Costs
were calculated by multiplying the number of preschool children
by per capita costs (Table 2). The extent of mortality reduction due
to vitamin A supplementation is somewhat contentious, ranging
from estimates as high as 23 percent [35,36] to insignificant
[24,37,38]. A recent study from northern India found reductions
in mortality of about 4 percent [39]. Thus, we assumed a range of
4 to 23 percent. Avoided mortality was converted to DALYs by
multiplying the number of deaths averted by life expectancy. The
National Prophylaxis Programme for Prevention of Blindness due
to Vitamin A Deficiency in India is implemented through the
existing Primary Health Care infrastructure [34]. Village-level
health subcenters, each serving a population of 5,000 (3,000 in
tribal, hilly, or inaccessible areas), conduct vitamin A supplemen-
tation. Drawing from state subcenter data [40], we estimated
subcenter coverage by conservatively assuming each subcenter
covers 3,000 people and then dividing the number of people
covered by the total state population. Because village-level health
subcenters serve only a fraction of the population in each state, we
included supplementation costs for all areas currently served by
health subcenters [40] as well as the additional costs of supple-
menting children in areas currently lacking subcenter coverage,
which would require additional resources for delivery [22]. The
supplementation coverage achievable was adjusted downward
according to an estimated rate of health worker absenteeism [41].
Given our assumptions regarding coverage and absenteeism, we
found that state coverage ranged from 20 percent in Uttar Pradesh
to 61 percent in Himachal Pradesh, with an average of 25 percent
coverage across our entire study area. However, our estimates did
not consider the costs for expansion, program infrastructure, or
other fixed costs, and we assumed that the effectiveness rates were
uncorrelated with subcenter coverage.
Industrial fortification of mustard oil with vitamin
A. Avertable morbidity and mortality were considered not just
among preschool children but also among new and expectant
mothers because broad-based fortification of a commonly con-
sumed food item, such as mustard oil, would increase the VA
Table 1. Effectiveness of interventions in reducing VAD
burden.
Intervention Percentage reduction
Bitot’s spots (children) 26–75
Night blindness (children) 46–100
Blindness (children) 43–75
Mortality (children) 4–23
doi:10.1371/journal.pone.0012046.t001
Table 2. Cost of each intervention.
Intervention Cost
Supplementation
Shipping, storage, delivery, and wastage for 2 doses of vitamin A per year US$0.07 (Rs. 2.58) per child per year [62]
Administrative and regulatory costs, training, promotional and educational materials, and program
monitoring and evaluation
US$ 0.08 (3.33Rs) per child per year [63]
Total (areas w/subcenters) US$0.15 (Rs. 5.91) per child per year
Total (areas w/o subcenters) US$0.65 (Rs. 26) per child per year [22]
Fortification
Cost to fortify 1 kg of oil US$0.001 (Rs. 0.045) to US$0.005 (Rs. 0.22) [63,64]
Administrative and regulatory costs, training, promotional and educational materials, and program
monitoring and evaluation (per kg of oil)
US$0.002 (Rs. 0.062) [63]
Bottling costs (per l of oil) US$0.09 (Rs. 3.75) [65,66]
GM fortification
Administrative and regulatory costs, training, promotional and educational materials, and program
monitoring and evaluation (per kg of oil)
US$0.002 (Rs. 0.062) [63]
Bottling costs (per l of oil) US$0.09 (Rs. 3.75) [65,66]
One-time regulatory approval cost US$5.6 million (22.7 crore Rs.) [66]
doi:10.1371/journal.pone.0012046.t002
VAD and Golden Mustard
PLoS ONE | www.plosone.org 4 August 2010 | Volume 5 | Issue 8 | e12046intake of the entire population. Population estimates for new and
expectant mothers for a given year are based on age-specific
fertility rates and female population numbers from each state.
We calculated morbidity and mortality efficacy based on
current vitamin A consumption, improved vitamin A (IVA) intake
with fortified mustard oil, and recommended daily allowances
(RDA), following methods used by Zimmermann and Qaim [13].
RDA values for preschool children and for new and expectant
mothers were estimated to be 400mg and 775mg, respectively [3].
IVA is calculated by adding current vitamin A consumption [3,42]
to current mustard oil consumption times a retinol concentration
of 18mg/g and a VA retention rate. Retention rates of VA
supplement during storage exceed 92 percent after six months
[43]. VA supplement has a retention rate of 78–90 percent after
brief, low-heat frying, which is how approximately 90 percent of
oil consumed is used [43]. Because the supply chain from producer
to retailer is fairly efficient, and because rural households typically
use mustard oil soon after purchase, we chose a conservative
retention rate of 80 percent. Mustard oil consumption among
preschoolers is estimated based on average consumption data (kg/
month/person/household) [44], state-specific household age struc-
ture, and age-specific consumption rates [44,45] and conserva-
tively scaled down based on income and age because the poorest
segments of a population tend to consume less mustard oil per
person than average [44] and children consume less than adults.
DALYs from averted morbidity and mortality were calculated
under the assumption that fortified mustard is available in the
same proportion for all consumers, and that for new and expectant
mothers the intervention prevents death among a different set of
women each year. The costs included the cost for the fortification
process itself as well as other costs to prevent vitamin A
degradation and ensure product quality, such as bottling and
quality control (Table 2). We assumed that all mustard oil
consumed is required to be fortified, and we explicitly accounted
for administrative and regulatory costs, training, promotional and
educational materials, and program monitoring and evaluation.
Because vitamin A fortificant degrades readily when exposed to
light, the costs of bottling in opaque containers was also
considered.
Biofortificationwith geneticallymodified mustard. Since
GM fortification and industrial fortification are similar delivery
strategies for vitamin A, the cost-effectiveness analyses of the two
interventions were alike except for parameter adjustments
regarding costs and vitamin A content (Table 2). Based on field
trials, in which pressed oil from genetically modified mustard seed
could contain as much as 600mg per gram of oil, we conservatively
assumed that GM-fortified mustard oil has a beta-carotene content
of 185mg/g [46], and that only 71 percent of the beta-carotene is
retainedaftercooking[47].The varietyof mustard being developed
for expression of beta-carotene accounts for 70–80 percent of the
mustard grown in India. Hence, we assume that only 75 percent of
the mustard seed that is pressed into oil is GM fortified. Based on
these assumptions, we calculated an effective concentration of
49.3mg of vitamin A per g of oil at the consumption level.
Costs related to the distribution, sale, and regulation of GM-
fortified oil were assumed to be the same as for industrially fortified
oil, since both would require bottling in opaque containers and
presumably require similar regulatory, monitoring, and enforce-
ment frameworks. However, there are no costs related to adding
artificial fortificant, since beta-carotene would occur naturally in
GM-fortified mustard seeds and the cold-pressed oil produced from
it. Instead, we incorporated a one-time fixed cost of US$5.6 million
(Rs. 22.7 crore) to account for the costs of licensing on the assum-
ption that the R&D has already been completed and the regulatory
mechanisms for licensing such products are already in place. We
apportionedthisamountamongthestatesconsideredinthisanalysis
according to their total rural population size and applied the same
rate to urban populations. We estimated that these fixed costs would
amount to approximately US$0.01 (Rs. 0.40) per person.
To prevent the escape of engineered genetic material into
natural ecosystems, the growing of genetically modified mustard
on a commercial scale could require bioconfinement practices by
farmers, as well as additional regulatory and monitoring activities
[48]. However, cost estimates for regulation of transgenic crops in
India do not yet exist because the policies themselves are still being
formulated, and there is a great deal of regulatory ambiguity
regarding transgenic crops. The most comparable example is Bt
cotton, which in 2002 became the first transgenic crop approved
for cultivation in India [49]. Farmers and others involved in cotton
production do not yet incur additional costs for producingB t
cotton other than a premium for the purchase of transgenic seeds.
Since GM-fortified mustard is not expected to be sold at an
additional premium and because the regulatory framework is still
unclear, we ignored any additional costs of growing GM-fortified
versus regular mustard.
Sensitivity analysis
Because of the uncertainty surrounding our assumed parame-
ters, we used a Monte Carlo sampling method to evaluate the
robustness of our results [50]. We found that our assumed
mortality range had a significant effect on the results. To more
accurately depict the range over which our results varied, we
adjusted the analysis to examine an optimistic scenario and a
conservative scenario. In the optimistic scenario we assumed a
mortality reduction rate of 23 percent, and in the conservative
scenario we assumed a mortality reduction rate of 4 percent. All
other parameters were varied over their full range to produce
confidence intervals around our different scenarios (see the
Supplementary Notes S2 for detailed information on sensitivity
analysis and Table S1 for parameter ranges).
Results
Our analysis estimated the effectiveness in reducing morbidity
and mortality associated with vitamin A deficiency through three
methods: supplementation for 1- to 4-year-olds, industrial fortifi-
cation of mustard oil, and GM fortification of mustard seed. Each
scenario was evaluated using a conservative efficacy rate (4
percent) and an optimistic efficacy rate (23 percent) of averted
mortality, and results were obtained for the number of DALYs and
deaths averted over a 20-year time frame. The costs of each
intervention are presented in Table 3, and the incremental cost-
effectiveness of each non-dominated intervention in $/DALY and
$/Death Averted are presented in Tables 4 and 5, respectively.
Table 3. Cost of intervention implementation.
Intervention Cost US$ (millions)
Supplementation 637 (607–667)
areas w/subcenters 36 (35–38)
areas w/o subcenters 600 (570–630)
Fortification 3,177 (3,099–3,255)
GM fortification 3,103 (3,028–3,179)
Note: parentheses denote 95 percent confidence intervals.
doi:10.1371/journal.pone.0012046.t003
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alternative is the difference in cost divided by the difference in
DALYs or deaths averted associated with each intervention. We
also calculated an internal rate of return for each intervention in
Table 6, though these are not incremental.
As shown in Table 4, we estimate that over a 20-year period,
GM fortification could avert the most DALYs (18 million–34
million) and deaths (113,000–654,000), but at approximately 5
times the cost of supplementation, which could avert 12 million–
28 million DALYs and 105,000–608,000 deaths. The incremental
cost of supplementation, evaluated at $23 (95 percent CI: 22–24)
to $50 (95 percent CI: 46–54) per DALY averted, is far less than
the incremental cost of GM fortification, $403 (95 percent CI:
389–418) to $450 (95 percent CI: 438–461) per DALY averted. A
similar relationship occurs when considering only deaths averted
(Table 5). However, these results ignore any fixed costs of
expanding supplementation services to populations without sub-
centers. Moreover, supplementation targets only young children
and does not alleviate the suffering of pregnant mothers. Industrial
fortification averts fewer DALYs and deaths at a greater cost than
both GM fortification and supplementation and thus is dominated
by both of them. Industrial fortification is strictly dominated by
GM fortification because it is assumed to have a lower vitamin A
content than GM-fortified oil.
The cost-effectiveness of supplementation varies depending on
health subcenter coverage. In areas where health subcenters exist,
the cost per DALY averted can be as low as $5t o$11 (or $200 to
$1,300 per death averted), whereas additional delivery costs
necessary in areas without subcenters result in an incremental cost-
effectiveness ratio of $42 to $90 per DALY averted (or $1,900 to
$11,100 per death averted). Of the DALYs avertable via
supplementation, 9.5 million (95 percent CI: 9.2–9.8) to 20.6
million (95 percent CI: 20.3–20.8) occur in areas lacking subcenter
coverage, versus 3.2 million (95 percent CI: 3.1–3.3) to 7.1 million
(95 percent CI: 7.0–7.2) in areas with existing subcenters.
Similarly, the number of avertable deaths is greater, 78,000 (95
percent CI: 75,000–81,000) to 450,000 (95 percent CI: 447,000–
453,000), in areas without subcenters than in areas with subcenter
coverage, 27,000 (95 percent CI: 26,000–28,000) to 158,000 (95
percent CI: 157,000–158,000).
The cost-effectiveness ratio for expanding supplementation to
all areas translates to an internal rate of return of 68–104 percent,
which far exceeds the internal rate of return of industrial
fortification (6–22 percent) and GM fortification (21–42 percent)
(Table 6). The internal rate of return for supplementation in areas
where health subcenters are located (142–195 percent) is greater
than the IRR in areas without subcenters (59–93 percent), again
because of greater delivery costs in those areas.
Estimates for DALYs and deaths averted for each intervention
exhibited significant variation among states and between rural and
urban areas (see Supplementary Table S2), but overall patterns
remained the same as those described above. VAD interventions
had higher cost-effectiveness ratios across all interventions in states
that had low underlying mortality rates, such as West Bengal and
Himachal Pradesh. Interventions also had higher cost-effectiveness
ratios in urban areas because of their lower baseline mortality
rates.
Discussion
Vitamin A supplementation, at US$23–$50 per DALY averted,
is much less costly than either fortification intervention. Because of
the substantially greater cost for GM fortification, the incremental
cost-effectiveness of this intervention is US$405–$450 per DALY
averted, though it would reach a wider swath of the population,
particularly pregnant mothers. Industrial fortification of mustard
oil, which averts fewer DALYs and costs more than either
supplementation or GM fortification, is not an attractive option for
policymakers under the assumptions we have made about costs
and benefits.
Our estimates for the cost-effectiveness of a vitamin A
supplementation program targeting preschool children are in line
with estimates previously reported in the literature, at least for
areas with subcenter coverage [51,52]. However, our cost-
effectiveness estimates for people without access to functioning
health subcenters, a situation that applies to some 70 percent of
Table 4. DALYs averted for each intervention over 20-year time horizon.
Intervention DALYs averted (millions) Incremental cost-effectiveness ($/DALY)
Low efficacy High efficacy Low efficacy High efficacy
Supplementation 12.7 (12.4–13.1) 27.6 (27.3–28.0) 50 (46–54) 23 (22–24)
Fortification 10.8 (10.5–11.1) 18.6 (18.2–19.0) Dominated Dominated
GM fortification 18.1 (17.8–18.5) 33.7 (33.2–34.1) 450 (438–461) 403 (389–418)
Note: Parentheses denote 95 percent confidence intervals. Each intervention is compared with immediately less effective and non-dominated alternative intervention.
doi:10.1371/journal.pone.0012046.t004
Table 5. Deaths averted for each intervention over 20-year time horizon.
Intervention Deaths averted (thousands) Incremental cost-effectiveness ($/death averted)
Low efficacy High efficacy Low efficacy High efficacy
Supplementation 105 (102–109) 608 (604–611) 6,100 (5,600–6,600) 1,000 (1,000–1,100)
Fortification 86 (84–88) 356 (349–362) Dominated Dominated
GM fortification 113 (110–116) 654 (647–660) 303,300 (310,000–297,100) 53,000 (48,700–57,900)
Note: Parentheses denote 95 percent confidence intervals. Each intervention is compared with immediately less effective and non-dominated alternative intervention.
doi:10.1371/journal.pone.0012046.t005
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difference may be due to the numerous assumptions in our analysis
intended to err on the conservative side of avertable disease
burden, as well as uncertainties about the cost of supplementation.
In particular, despite recent evidence that VAD supplementation
is effective in significantly reducing morbidity [36], our lack of data
on existing levels of supplementation required us to apply
conservative effectiveness rates, since the incremental effectiveness
of any intervention would be expected to diminish with any
underlying level of supplementation greater than zero.
Based on the few formal cost-effectiveness studies of vitamin A
fortification comparable to ours, fortifying oil in India may be
more costly than interventions in other countries that use different
vitamin A delivery vectors. For example, in Central America the
annual cost of sugar fortification has been estimated at around
US$1 per high-risk person reached (i.e., young children and
women of childbearing age) [53,54], and a study of wheat
fortification in the Philippines indicated an annual cost of $1.3 to
$2.3 per child with inadequate vitamin A intake [55]. These
reported costs are less than our estimate for fortification of
approximately $4.50 per year per person at risk (i.e., pregnant
women and children). Such differences may be at least partly
related to India’s large number of small, disaggregated mustard
oil producers—in contrast to the concentrated manufacture of
fortification vehicles evaluated in other studies—and the conse-
quent additional difficulty and cost of ensuring that the oil is
fortified.
Other analyses of GM fortification have tended to find that
introducing biofortified products may be less costly than our
estimates for GM mustard. In an ex ante analysis of golden rice in
the Philippines, Zimmerman and Qaim [13] estimated that
introducing GM-fortified rice would result in a gain in DALYs
of 15,000–85,000 per annum, which is significantly less than the
effectiveness of GM mustard, even when accounting for the
difference in population size. The expected cost of GM rice,
including R&D costs, was estimated to be $10.7 million, with a
continuing cost of $0.5 million per annum. Over a 20-year time
frame with a 3 percent discount rate, this suggests a total cost of
approximately $18.6 million. This cost is significantly less than our
estimates for GM mustard, but unlike GM mustard, the estimates
for GM rice assumed no significant additional costs associated with
distribution. Zimmerman and Qaim estimated an IRR of 66–133
percent, which is greater than our estimates for GM fortification of
mustard oil in India. This disparity is partly due to the significantly
higher per capita income assumed for the Philippines—$1,030
versus the average $344 assumed in our analysis. Stein and
colleagues [10], using new estimates for the vitamin A content of
GM rice, estimated that introducing Golden Rice could result in a
gain of 204,000–1,382,000 DALYs per annum, which is similar to
our calculation for GM mustard. However, they estimated that the
total costs for introducing Golden Rice in India, including
development, breeding, regulation, dissemination, marketing,
and maintenance efforts, would amount to only $16.5 million–
$21.5 million over 20 years. Using the same framework,
Meenakshi and collegues [18] evaluated the prospective introduc-
tion of a number of GM-fortified crops into several countries and
also found generally lower costs and less effectiveness, though the
range was great.
In contrast to our finding that supplementation was more cost-
effective than fortification, other studies comparing alternative
vitamin A interventions have found that fortification can be the
more attractive option [53,55,56]. However, these studies
generally acknowledged that supplementation is more appropriate
in settings where the fortified food product is not consumed in
sufficient amounts. Furthermore, although GM fortification may
have a lower cost-effectiveness ratio than supplementation in some
cases, it may not deliver adequate amounts of vitamin A and may
be insufficient as a stand-alone strategy [11]. Hence, the optimal
decision depends on the consumption patterns of the fortified food,
and the two strategies can be complementary. For instance, even
though our results suggest that supplementation has a substantially
lower cost-effectiveness ratio, implementation of a universal
supplementation program in India has been problematic. After
30 years, the National Prophylaxis Programme for Prevention of
Blindness has achieved coverage of only about 30 percent
[6,17,22], and controversy over its implementation and effective-
ness [57] has further complicated progress.
GM fortification, on the other hand, offers some advantages
over supplementation even if the incremental cost-effectiveness
ratio is large. Unlike periodic supplementation, GM fortification
would provide a continual source of vitamin A and is thus more
likely to result in a sustained rise in serum retinol levels [27,58],
providing sustained protection from anemia and infectious disease.
Additionally, our analysis shows that GM fortification of mustard
oil might avert a substantially greater disease burden than
supplementation alone, mostly because it would benefit the entire
population, rather than a single targeted age group. Also, seed
production and distribution in India are relatively centralized,
facilitating implementation and enforcement. However, GM
fortification faces some challenges. Although mustard oil is a
good vehicle for supplying beta-carotene in states where mustard
oil is widely consumed, people in many parts of the country do not
consume mustard oil.
Introduction of GM fortified seed may also face acceptance
hurdles. Our discussions with farmers suggest that although the
introduction of GM-fortified seed would be readily accepted, the
color of the resulting oil may face some resistance from consumers,
necessitating additional costs for education and awareness
campaigns. There also may be regulatory hurdles to widespread
use of GM technologies.
In summary, our analysis suggests that vitamin A supplemen-
tation is a less costly method of improving the vitamin A status of
vulnerable populations in India but would avert fewer DALYs and
deaths than fortification via genetically recombinant mustard oil.
GM mustard could reduce VAD disease burden by a substantially
greater degree because of its potentially wider reach. However, our
analysis does not include the fixed costs associated with expanding
supplementation in areas currently without subcenter coverage.
Our results can help inform the selection of VAD reduction
strategies at the state level. They indicate that GM fortification of
mustard oil could be used to reach vulnerable populations,
especially those that do not readily benefit from supplementation
Table 6. Internal rates of return for each intervention.
Intervention Internal Rate of Return
Low efficacy High efficacy
Supplementation 68 (65–70) 104 (102–107)
areas w/subcenters 142 (139–145) 195 (192–198)
areas w/o subcenters 59 (56–61) 93 (90–95)
Fortification 6 (5–7) 22 (21–22)
GM fortification 22 (21–23) 43 (42–44)
Note: Parentheses denote 95 percent confidence intervals. Internal rates of
return are not incremental.
doi:10.1371/journal.pone.0012046.t006
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Primary Health Care facilities. The optimal approach to address-
ing VAD in India thus will likely include a mix of strategies, given
their relative advantages and disadvantages and the cultural and
socioeconomic variations that exist across India. In mustard-
consuming states at least, GM fortification of mustard oil has the
potential to substantially reduce VAD. States that do not consume
mustard oil, however, must continue to rely on supplementation
to improve their VA status or develop alternative fortification
vehicles.
Supporting Information
Notes S1 Mustard oil consumption in India.
Found at: doi:10.1371/journal.pone.0012046.s001 (0.03 MB
DOC)
Notes S2 Sensitivity analysis.
Found at: doi:10.1371/journal.pone.0012046.s002 (0.04 MB
DOC)
Figure S1 Total domestic consumption of edible oil, 1972–2006,
by type. Note: Consumption for 2006 is an estimate. Source:
United States Department of Agriculture 2006.
Found at: doi:10.1371/journal.pone.0012046.s003 (0.41 MB TIF)
Figure S2 Monthly per capita purchases of mustard oil by
household income in rural and urban households of Rajasthan,
Uttar Pradesh, Bihar, and Madhya Pradesh, 2005. Source: IMRB
International (2006).
Found at: doi:10.1371/journal.pone.0012046.s004 (2.84 MB TIF)
Table S1 Parameter values for sensitivity analysis.
Found at: doi:10.1371/journal.pone.0012046.s005 (0.11 MB
DOC)
Table S2 State-specific cost-effectiveness calculations ($/DALY
averted).
Found at: doi:10.1371/journal.pone.0012046.s006 (0.05 MB
DOC)
Acknowledgments
Paula Whitacre, Saraswathi Bulusu, Vibha Dhawan, Cherian George,
Rajan Kapoor, Anand Lakshman, Rakesh Mittal, S.R. Rao, H.B. Singh,
and Satyajeet Yadav provided substantive and valuable input to the report.
Author Contributions
Conceived and designed the experiments: JC EYK RL. Analyzed the data:
JC EYK RL. Wrote the paper: JC EYK RL.
References
1. West Jr. K (2002) Extent of vitamin A deficiency among preschool children and
women of reproductive age. Journal of Nutrition 132: 2857–2866.
2. Kapil U (2001) National consultation on benefits and safety of administration of
vitamin A to pre-school children and pregnant and lactating women. Indian
Pediatrics 38: 37–42.
3. Toteja G, Singh P (2004) Micronutrient Profile of Indian Population. New
Delhi: Indian Council of Medical Research.
4. Mason J, Bailes A, Beda-Andourou M, Copeland N, Curtis T, et al. (2005)
Recent trends in malnutrition in developing regions: vitamin A deficiency,
anemia, iodine deficiency, and child underweight. Food and Nutrition Bulletin
26: 59–108.
5. NNMB (2003) Prevalence of Micronutrient Deficiencies. NNMB Technical
Report No. 22.
6. IIPS (2000) National Family Health Survey (NFHS-2), 1998–99: India. Mumbai:
International Institute for Population Sciences.
7. Christian P (2002) Recommendations for indicators: night blindness during
pregnancy— a simple tool to assess vitamin A deficiency in a population. Journal
of Nutrition 132: 2884–2888.
8. Sommer A, West KP (1996) Vitamin A Deficiency: Health, Survival, and Vision.
New York: Oxford University Press.
9. Paine JA, Shipton CA, Chaggar S, Howells RM, Kennedy MJ, et al. (2005)
Improving the nutritional value of Golden Rice through increased pro-vitamin A
content. Nat Biotech 23: 482–487.
10. Stein AJ, Sachdev HPS, Qaim M (2006) Potential impact and cost-effectiveness
of Golden Rice. Nat Biotech 24: 1200–1201.
11. Dawe D, Robertson R, Unnevehr L (2002) Golden rice: what role could it play
in alleviation of vitamin A deficiency? Food Policy 27: 541–560.
12. Egana NE (2003) Vitamin A deficiency and Golden Rice—a literature review.
Journal of Nutritional & Environmental Medicine 13: 169–184.
13. Zimmerman R, Qaim M (2004) Potential health benefits of Golden Rice: a
Philippine case study. Food Policy 29: 147–168.
14. Agricultural Biotechnology Support Project (2003) Final Technical Report. East
Lansing, Michigan: Michigan State University.
15. Shewmaker CK, Sheehy JA, Daley M, Colburn S, Ke DY (1999) Seed-specific
overexpression of phytoene synthase: increase in carotenoids and other
metabolic effects. Plant Journal 20: 401–412.
16. West Jr. K, Darnton-Hill I (2001) Vitamin A deficiency. In: Semba RD,
Bloem MW, eds. Nutrition and Health in Developing Countries. Totowa, NJ:
Humana Press. pp 257–306.
17. Micronutrient Initiative (2005) Controlling Vitamin & Mineral Deficiencies in
India: Meeting the Goal. New Delhi: Micronutrient Initiative.
18. Meenakshi JV, Johnson N, Manyong VM, Groote HD, Javelosa J, et al. (2007)
How cost-effective is biofortification in combating micronutrient malnutrition?
An ex-ante assessment. Washington, DC: HarvestPlus Working Paper No.2.
19. Stein AJ, Sachdev HPS, Qaim M (2008) Genetic engineering for the poor:
Golden Rice and public health in India. World Development 36: 144–158.
20. Rushby JAF, Hanson K (2001) Calculating and presenting disability adjusted life
years (DALYs) in cost-effectiveness analysis. Health Policy and Planning 16:
326–331.
21. World Bank (1993) World Development Report: Investing in Health.
Washington, DC: International Bank for Reconstruction and Development.
22. Lakshman A (2006) National Programme Officer for Vitamin A Supplemen-
tation, Micronutrient Initiative. Personal communication to Jeffrey Chow, 30
June.
23. Chandigarh National Informatics Centre (2007) Chandigarh in figures:
economic indicators-2005. http://chandigarh.gov.in/knowchd_stat.htm (ac-
cessed: March 13, 2007).
24. Cohen N, Rahman H, Mitra M, Sprague J, Islam S, et al. (1987) Impact of
massive doses of vitamin A on nutritional blindness in Bangladesh. American
Journal of Clinical Nutrition 45: 970–976.
25. Rahmathullah L, Underwood B, Thulasiraj R, Milton R, Ramaswamy K, et al.
(1990) Reduced mortality among children in southern India receiving a small
weekly dose of vitamin A. New England Journal of Medicine 323: 929–935.
26. Rao BRH, Klontz CE, Benjamin V, Rao PSS, Begum A, et al. (1961) Nutrition
and health status survey of school children. Indian Journal of Pediatrics 28:
39–50.
27. Solon FS, Fernandez TL, Latham MC, Popkin BM (1979) An evaluation of
strategies to control vitamin A deficiency in the Philippines. American Journal of
Clinical Nutrition 32: 1445–1453.
28. Swami H, Thakur J, Bhatia S (2002) Mass supplementation of vitamin A linked
to National Immunization Day. Indian Journal of Pediatrics 69: 675–678.
29. Swaminathan M, Susheela T, Thimmayamma B (1970) Field prophylactic trial
with a single annual oral massive dose of vitamin A. American Journal of
Clinical Nutrition 23: 119–122.
30. Daulaire N, Starbuck E, Houston R, Church M, Stukel T, et al. (1992)
Childhood mortality after a high dose of vitamin A in a high risk population.
BMJ 304: 207–210.
31. Katz J, West KP, Khatry SK, Pradhan EK, LeClerq SC, et al. (2000) Maternal
low-dose vitamin A or ß-carotene supplementation has no effect on fetal loss and
early infant mortality: a randomized cluster trial in Nepal. American Journal of
Clinical Nutrition 71: 1570–1576.
32. West Jr. K, Katz J, Shrestha S, LeClerq S, Khatry S, et al. (1995) Mortality of
infants ,6 mo of age supplemented with vitamin A: a randomized, double-
masked trial in Nepal. American Journal of Clinical Nutrition 62: 143–148.
33. WHO/CHD Immunisation-Linked Vitamin A Supplementation Study Group
(1998) Randomised trial to assess benefits and safety of vitamin A supplemen-
tation linked to immunisation in early infancy. Lancet 352: 1257–1263.
34. Indian Council of Medical Research (2004) Recommendation of National
Workshop on Micronutrients Held on 24–25th November, 2003 at Delhi and
Organized by Indian Council of Medical Research on Behalf of Ministry of
Health and Family Welfare. New Delhi: Government of India, Ministry of
Health and Family Welfare, Department of Family Welfare, CH Section.
No.Z.28020/50/2003-CH.
35. Beaton G, Martorell R, Aronson K, Edmonston B, McCabe G, et al. (1994)
Vitamin A supplementation and child morbidity and mortality in developing
countries. Food and Nutrition Bulletin 15.
36. Bhutta Z, Ahmed T, Black R, Cousens S, Dewey K, et al. (2008) What works?
Interventions for maternal and child undernutrition and survival. Lancet 371:
417–440.
VAD and Golden Mustard
PLoS ONE | www.plosone.org 8 August 2010 | Volume 5 | Issue 8 | e1204637. Herrera MG, Nestel P, el Amin A, Fawzi WW, Mohamed KA, et al. (1992)
Vitamin A supplementation and child survival. Lancet 340: 267–271.
38. Vijayaraghavan K, Radhaiah G, Prakasam BS, Sarma KV, Reddy V (1990)
Effect of massive dose vitamin A on morbidity and mortality in Indian children.
Lancet 336: 1342–1345.
39. Awasthi S, Peto R, Read S, Bundy D (2007) Six-monthly vitamin A from 1 to 6
years of age DEVTA: Cluster-randomised trial in 1 million children in North
India, 2007-04-17, Istanbul.
40. NRHM (2006) Annual Report 2005–2006. New Delhi: National Rural Health
Mission, Ministry of Health and Family Welfare, Government of India.
41. Chaudhury N, Hammer J, Kremer M, Muralidharan K, Rogers F (2006)
Missing in action: teacher and health worker absence in developing countries.
Journal of Economic Perspectives 20: 91–116.
42. NNMB (2002) Diet and nutritional status of rural population. Hyderabad:
National Institute of Nutrition.
43. Nicholas Piramal India Limited (2006) Human nutrition & health—fortification.
http://www.vfcdnicholas.com/hnh/fortification6.htm (accessed: November 15,
2006).
44. NNMB (1999) Report of Second Repeat Survey—Rural. Hyderabad: National
Nutrition Monitoring Bureau.
45. NSS (2001) NSS 55th Round. New Delhi: National Sample Survey Organisation
Ministry of Statistics & Programme Implementation Government of India.
46. TERI (2006) Vitamin A socioeconomic review. New Delhi: Tata Energy
Research Institute.
47. Manorama R, Rukmini C (1991) Effect of processing on ß-carotene retention in
crude palm oil and its products. Food Chemistry 42: 253–264.
48. National Research Council (2004) Biological Confinement of Genetically
Engineered Organisms. Washington, DC: National Academies Press.
49. Barwale RB, Gadwal VR, Zehr U, Zehr B (2004) Prospects for Bt cotton
technology in India. Journal of Agrobiotechnology Management & Economics 7:
23–26.
50. McKay MD, Beckman RJ, Conover WJ (1979) A comparison of three methods
for selecting values of input variables in the analysis of output from a computer
code. Technometrics 21: 239–245.
51. Caulfield L, Richard S, Rivera J, Musgrove P, Black R (2006) Stunting, wasting,
and micronutrient deficiency disorders. In: Jamison D, Alleyne G, Breman J,
Claeson M, Evans D, et al. (2006) Disease Control Priorities in Developing
Countries, 2nd edition. Washington, DC: United States National Institutes of
Health.
52. Houston R (2003) Why They Work: An Analysis of Three Successful Public
Health Interventions. MOST (USAID Micronutrient Program).
53. Phillips M, Sanghvi T, Sua ´rez R, McKigney J, Fiedler J (1996) The costs and
effectiveness of three vitamin A interventions in Guatemala. Social Science and
Medicine 42: 1661–1668.
54. Mora JO, Dary O, Chinchilla D, Arroyave G (2000) Vitamin A Sugar
Fortification in Central America: Experience and Lessons Learned. MOST
(USAID Micronutrient Program).
55. Fiedler J, Dado D, Maglaland H, Juban N, Capistrano M, et al. (2000) Cost
analysis as a vitamin A program design and evaluation tool: a case study of the
Philippines. Social Science and Medicine 51: 223–242.
56. Dary O (1997) Sugar fortification with vitamin A: a Central American
contribution to the developing world. Food Fortification to End Micronutrient
Malnutrition: State of the Art Satellite Conference of the XVIth International
Congress of Nutrition, Symposium Report. Ottawa: Micronutrient Initiative.
57. Vijayaraghavan K (2006) Micronutrient Policies and Programs in India:
Vitamin A Deficiency Situational Assessment to Guide USAID Investments.
NIN.
58. Arroyave G, LA M, JR A (1981) The effect of vitamin A fortification of sugar on
the serum vitamin A levels of preschool Guatemalan children: a longitudinal
evaluation. American Journal of Clinical Nutrition 34: 41–49.
59. Toteja G, Singh P, et al. (2001) Micronutrient deficiency disorders in 16 districts
of India. Part 1 Report of an ICMR task force study-District Nutrition Program.
New Delhi: Indian Council of Medical Research.
60. National Institute of Nutrition (NIN) (2001) Annual Report. Hyderabad:
National Institution of Nutrition.
61. Chakravarty I, Ghosh K (2000) Micronutrient malnutrition—present status and
future remedies. Journal of the Indian Medical Association 98(9): 539–42.
62. Anand K, Sankar R, Kapoor SK, Pandav CS (2004) Cost of syrup versus capsule
form of vitamin A supplementation. Indian Pediatrics 41: 377–383.
63. Micronutrient Initiative (MI) (2006) India Micronutrient National Investment
Plan 2007–2011. New Delhi: Micronutrient Initiative.
64. Nicholas Piramal India Ltd., Vitamins and Fine Chemicals Division (2006)
Pamphlet. NicoRich Oil: Vitamin A for Oil Fortification.
65. Bhushan C (2006) Bottled loot: the structure and economics of the Indian bottled
water industry. Frontline 23(7): http://www.hinduonnet.com/fine/f2307/
stories/20060421006702300.htm (accessed: November 15, 2006).
66. George C (2005) Technical Director, Monsanto. Personal communication to
Jeffrey Chow, Eili Klein, and Ramanan Laxminarayan, 2 December.
VAD and Golden Mustard
PLoS ONE | www.plosone.org 9 August 2010 | Volume 5 | Issue 8 | e12046